The UK National Health Service (NHS) Supply Chain has awarded £184m ($243.7m) tender to Cambridge Heartwear to supply its HeartSense cardiac monitoring technology.
The agreement covers the rollout of the portable, multi-channel electrocardiogram (ECG) device at primary and secondary care, and civil service departments across the UK.
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
HeartSense is a wirelessly charged, reusable wearable device that transmits continuous, real-time ECG readings directly to a mobile phone.
The agreement permits Integrated Care Boards to use the monitoring system at scale, enabling patients to capture diagnostic data in home and community settings.
The initiative aims to identify heart rhythm abnormalities earlier, assist in the prevention of strokes and heart failure, and reduce waiting times across hospital departments.
Designed with an ergonomic form intended to address gaps in cardiovascular care for women, the device combines multi-channel ECG recording with adaptive AI.
The technology is supported by 86 patents and has been engineered in Cambridge and manufactured in Britain to provide clinicians with remote data for earlier clinical intervention.
It holds UKCA approval as well as ISO 13845 certification. Applications for 510(k) clearance with the US Food and Drug Administration (FDA) are currently underway.
Cambridge Heartwear founder professor Rameen Shakur said: “We did not have a UK ECG manufacturer and reporter until now. HeartSense is the world’s first medical-grade, AI-powered, multi-channel ECG wearable and demonstrates what can be achieved when clinicians, engineers and AI specialists work together.
“We want to help move healthcare towards earlier diagnosis, better prevention and improved outcomes for patients across the NHS.”
Cambridge Heartwear is a medical technology company based at Cambridge Science Park and originated from the University of Cambridge.
The organisation develops AI-driven wearable devices designed to improve access to cardiovascular diagnostics and support clinical decision-making.
